As part of our ongoing commitment to building a greener and more responsible future, we are happy to announce the completion of the installation of 540 solar panels in one of our facilities. This action reinforces our dedication to sustainability and aligns with the Sustainable Development Goals (SDGs) outlined in the 2030 Agenda.
What does this mean for the environment?
With this installation, we are making a significant contribution to the environment by:
- Reducing our CO2 emissions by 130 tons annually, equivalent to the amount absorbed by over 6,000 trees.
- Achieving energy efficiency improvements of 18% to 30%, allowing us to use resources more responsibly.
- Generating clean, renewable energy, enough to power approximately 150 homes per year.
A commitment to positive change
This solar energy installation, with a capacity of 313.2 kWp, not only represents a significant reduction in our carbon footprint but also reaffirms our commitment to transforming our operations into a source of clean and sustainable energy. We have covered 1500 m² of our space with solar panels, marking a significant step in the fight against climate change.
Our commitment to sustainability does not stop here. We aim at driving projects for a brighter future where technology and respect for the environment go hand in hand. This is just the beginning of a series of initiatives that align our operations with sustainability and social responsibility principles.
Together, we are moving toward a greener, cleaner future for all!
News
October 01, 2024
We are moving towards a more sustainable future with solar energy!
Explore more
Resources
Webinar: Exploring key regulatory considerations to ensure patient safety in the gene therapy space
In July, a panel of expert speakers—Christine Lebec (Sensorion), Leigh Shaw (SpliceBio), Nathalie Clement (Siren Biotechnology), and María Orío (Viralgen)—came together to explore the evolving regulatory landscape in the cell and gene therapy (CGT)...
READ MORE
July 09, 2025

News
Viralgen Joins Orphan Therapeutics Accelerator Clinical Development Network as a Manufacturing Partner to Advance Rare Disease Therapies
Viralgen brings strong AAV gene therapy manufacturing capabilities to growing group of partners supporting new model for developing and commercializing orphan drugs Boston, MA & San Sebastian, Spain - May 14, 2025 – Orphan Therapeutics Accelerator...
READ MORE
May 14, 2025

News
Viralgen collaborates with Trogenix to advance AAV gene therapy for glioblastoma
Viralgen accelerates clinical development process: scaling manufacturing and completing GMP production of Trogenix’s AAV gene therapy in under 12 months. San Sebastián, Spain, 6 May 2025 – Viralgen, a leading contract development and manufacturing...
READ MORE
May 06, 2025